Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Gains from Sales and Divestitures (2022 - 2025)

Historic Gains from Sales and Divestitures for Taysha Gene Therapies (TSHA) over the last 4 years, with Q3 2025 value amounting to $1.2 million.

  • Taysha Gene Therapies' Gains from Sales and Divestitures rose 28578.9% to $1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 million, marking a year-over-year increase of 28578.9%. This contributed to the annual value of $323031.0 for FY2024, which is 4200.41% down from last year.
  • As of Q3 2025, Taysha Gene Therapies' Gains from Sales and Divestitures stood at $1.2 million, which was up 28578.9% from $1.2 million recorded in Q2 2025.
  • Over the past 5 years, Taysha Gene Therapies' Gains from Sales and Divestitures peaked at $1.2 million during Q2 2025, and registered a low of $17334.0 during Q1 2024.
  • For the 4-year period, Taysha Gene Therapies' Gains from Sales and Divestitures averaged around $543533.7, with its median value being $546141.0 (2022).
  • Its Gains from Sales and Divestitures has fluctuated over the past 5 years, first tumbled by 9310.22% in 2024, then skyrocketed by 595364.02% in 2025.
  • Quarter analysis of 4 years shows Taysha Gene Therapies' Gains from Sales and Divestitures stood at $628921.0 in 2022, then dropped by 11.44% to $556989.0 in 2023, then crashed by 42.0% to $323031.0 in 2024, then surged by 285.79% to $1.2 million in 2025.
  • Its Gains from Sales and Divestitures stands at $1.2 million for Q3 2025, versus $1.2 million for Q2 2025 and $1.0 million for Q1 2025.